Brimica Genuair (aclidinium;formoterol fumarate dihydrate)
- Region
- 🇪🇺 EU
- Active substance
- aclidinium;formoterol fumarate dihydrate
- Company
- Azurity Pharmaceuticals Ireland Ltd.
- Status
- Authorised
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- EU approval
- Wed 19 Nov 2014
- Application
- EMEA/H/C/003969
- ATC
- R03AL05
- Official record
- www.ema.europa.eu
Indication
Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Regulatory milestones
No milestones recorded in the last year.
Follow Brimica Genuair
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.